Back to the list
Congress: ECR25
Poster Number: C-25665
Type: Poster: EPOS Radiologist (scientific)
Authorblock: M. Thormann1, H-J. Meyer2, A. Wienke3, J. Borggrefe4, A. Surov4; 1Magdeburg/DE, 2Leipzig/DE, 3Halle/DE, 4Minden/DE
Disclosures:
Maximilian Thormann: Nothing to disclose
Hans-Jonas Meyer: Nothing to disclose
Andreas Wienke: Nothing to disclose
Jan Borggrefe: Nothing to disclose
Alexey Surov: Nothing to disclose
Keywords: Oncology, CT, Computer Applications-General, Cancer
References

[1]      Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 2019;48:16–31. https://doi.org/10.1093/ageing/afy169.

[2]      Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 2011;12:489–95. https://doi.org/10.1016/S1470-2045(10)70218-7.

[3]      Sun G, Li Y, Peng Y, Lu D, Zhang F, Cui X, et al. Can sarcopenia be a predictor of prognosis for patients with non-metastatic colorectal cancer? A systematic review and meta-analysis. Int J Colorectal Dis 2018;33:1419–27. https://doi.org/10.1007/s00384-018-3128-1.

[4]      Deng HY, Zha P, Peng L, Hou L, Huang KL, Li XY. Preoperative sarcopenia is a predictor of poor prognosis of esophageal cancer after esophagectomy: a comprehensive systematic review and meta-analysis. Diseases of the Esophagus 2019;32:1–10. https://doi.org/10.1093/DOTE/DOY115.

[5]      Surov A, Pech M, Gessner D, Mikusko M, Fischer T, Alter M, et al. Low skeletal muscle mass is a predictor of treatment related toxicity in oncologic patients. A meta-analysis. Clinical Nutrition 2021;40:5298–310. https://doi.org/10.1016/j.clnu.2021.08.023.

[6]      Surov A, Wienke A. Prevalence of sarcopenia in patients with solid tumors: A meta-analysis based on 81,814 patients. Journal of Parenteral and Enteral Nutrition 2022. https://doi.org/10.1002/JPEN.2415.

[7]      Cohen S, Nathan JA, Goldberg AL. Muscle wasting in disease: molecular mechanisms and promising therapies. Nat Rev Drug Discov 2015;14:58–74. https://doi.org/10.1038/NRD4467.

[8]      Armstrong VS, Fitzgerald LW, Bathe OF. Cancer-Associated Muscle Wasting—Candidate Mechanisms and Molecular Pathways. International Journal of Molecular Sciences 2020, Vol 21, Page 9268 2020;21:9268. https://doi.org/10.3390/IJMS21239268.

[9]      Sakai H, Asami M, Naito H, Kitora S, Suzuki Y, Miyauchi Y, et al. Exogenous insulin-like growth factor 1 attenuates cisplatin-induced muscle atrophy in mice. J Cachexia Sarcopenia Muscle 2021;12:1570–81. https://doi.org/10.1002/JCSM.12760.

[10]    Surov A, Pech M, Gessner D, Mikusko M, Fischer T, Alter M, et al. Low skeletal muscle mass is a predictor of treatment related toxicity in oncologic patients. A meta-analysis. Clinical Nutrition 2021;40:5298–310. https://doi.org/10.1016/j.clnu.2021.08.023.

[11]    Takenaka Y, Oya R, Takemoto N, Inohara H. Predictive impact of sarcopenia in solid cancers treated with immune checkpoint inhibitors: a meta-analysis. J Cachexia Sarcopenia Muscle 2021;12:1122–35. https://doi.org/10.1002/jcsm.12755.

[12]    Simonsen C, de Heer P, Bjerre ED, Suetta C, Hojman P, Pedersen BK, et al. Sarcopenia and Postoperative Complication Risk in Gastrointestinal Surgical Oncology. Ann Surg 2018;268:58–69. https://doi.org/10.1097/SLA.0000000000002679.

[13]    Thormann M, Hinnerichs M, Barajas Ordones F, Saalfeld S, Perrakis A, Croner R, et al. Sarcopenia is an independent prognostic factor in patients with pancreatic cancer – a meta-analysis. Acad Radiol 2022.

[14]    Pamoukdjian F, Bouillet T, Lévy V, Soussan M, Zelek L, Paillaud E. Prevalence and predictive value of pre-therapeutic sarcopenia in cancer patients: A systematic review. Clinical Nutrition 2018;37:1101–13. https://doi.org/10.1016/j.clnu.2017.07.010.

[15]    Petermann-Rocha F, Balntzi V, Gray SR, Lara J, Ho FK, Pell JP, et al. Global prevalence of sarcopenia and severe sarcopenia: a systematic review and meta-analysis 2021. https://doi.org/10.1002/jcsm.12783.

[16]    Martin L, Birdsell L, MacDonald N, Reiman T, Clandinin MT, McCargar LJ, et al. Cancer cachexia in the age of obesity: Skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. Journal of Clinical Oncology 2013;31:1539–47. https://doi.org/10.1200/JCO.2012.45.2722/ASSET/IMAGES/ZLJ9991033200003.JPEG.

[17]    Cederholm T, Barazzoni R, Austin P, Ballmer P, Biolo G, Bischoff SC, et al. ESPEN guidelines on definitions and terminology of clinical nutrition. Clin Nutr 2017;36:49–64. https://doi.org/10.1016/J.CLNU.2016.09.004.

[18]    Ní Bhuachalla ÉB, Daly LE, Power DG, Cushen SJ, MacEneaney P, Ryan AM. Computed tomography diagnosed cachexia and sarcopenia in 725 oncology patients: is nutritional screening capturing hidden malnutrition? J Cachexia Sarcopenia Muscle 2018;9:295–305. https://doi.org/10.1002/JCSM.12258.

[19]    Couderc AL, Liuu E, Boudou-Rouquette P, Poisson J, Frelaut M, Montégut C, et al. Pre-Therapeutic Sarcopenia among Cancer Patients: An Up-to-Date Meta-Analysis of Prevalence and Predictive Value during Cancer Treatment. Nutrients 2023, Vol 15, Page 1193 2023;15:1193. https://doi.org/10.3390/NU15051193.

[20]    von Haehling S, Anker MS, Anker SD. Prevalence and clinical impact of cachexia in chronic illness in Europe, USA, and Japan: facts and numbers update 2016. J Cachexia Sarcopenia Muscle 2016;7:507–9. https://doi.org/10.1002/JCSM.12167.

[21]    Shafiee G, Keshtkar A, Soltani A, Ahadi Z, Larijani B, Heshmat R. Prevalence of sarcopenia in the world: A systematic review and meta- analysis of general population studies. J Diabetes Metab Disord 2017;16:1–10. https://doi.org/10.1186/S40200-017-0302-X/FIGURES/5.

[22]    Whiting PF. QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies. Ann Intern Med 2011;155:529. https://doi.org/10.7326/0003-4819-155-8-201110180-00009.

[23]    Zamora J, Abraira V, Muriel A, Khan K, Coomarasamy A. Meta-DiSc: A software for meta-analysis of test accuracy data. BMC Med Res Methodol 2006;6:31. https://doi.org/10.1186/1471-2288-6-31.

[24]    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177–88. https://doi.org/10.1016/0197-2456(86)90046-2.

[25]    Papadopoulou SK, Tsintavis P, Potsaki G, Papandreou D. Differences in the Prevalence of Sarcopenia in Community-Dwelling, Nursing Home and Hospitalized Individuals. A Systematic Review and Meta-Analysis. J Nutr Health Aging 2020;24:83–90. https://doi.org/10.1007/S12603-019-1267-X.

[26]    Cruz-Jentoft AJ, Landi F, Schneider SM, Zúñiga C, Arai H, Boirie Y, et al. Prevalence of and interventions for sarcopenia in ageing adults: a                    systematic review. Report of the International Sarcopenia Initiative (EWGSOP and                    IWGS). Age Ageing 2014;43:748–59. https://doi.org/10.1093/AGEING/AFU115.

[27]    Smith MR, Saad F, Egerdie B, Sieber PR, Tammela TLJ, Ke C, et al. Sarcopenia during androgen-deprivation therapy for prostate cancer. Journal of Clinical Oncology 2012;30:3271–6. https://doi.org/10.1200/JCO.2011.38.8850/SUPPL_FILE/388850_PV.PDF.

[28]    Bowen TS, Schuler G, Adams V. Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training. J Cachexia Sarcopenia Muscle 2015;6:197–207. https://doi.org/10.1002/JCSM.12043.

[29]    Woo J, Cheung CK, Ho SC, Mak YT, Swaminathan R. Protein nutritional status in elderly Chinese in Hong Kong. Eur J Clin Nutr 1988;42:903–9.

[30]    Guthold R, Stevens GA, Riley LM, Bull FC. Worldwide trends in insufficient physical activity from 2001 to 2016: a pooled analysis of 358 population-based surveys with 1·9 million participants. Lancet Glob Health 2018;6:e1077–86. https://doi.org/10.1016/S2214-109X(18)30357-7.

[31]    Li N, Lu B, Luo C, Cai J, Lu M, Zhang Y, et al. Incidence, mortality, survival, risk factor and screening of colorectal cancer: A comparison among China, Europe, and northern America. Cancer Lett 2021;522:255–68. https://doi.org/10.1016/J.CANLET.2021.09.034.

[32]    Donkers H, Fasmer KE, Mcgrane J, Pijnenborg JMA, Bekkers R, Haldorsen IS, et al. The role of sarcopenic obesity in high-grade endometrial cancer. International Journal of Gynecology & Obstetrics 2021;154:248–55. https://doi.org/10.1002/IJGO.13591.

[33]    Lee J, Chang CL, Lin J Bin, Wu MH, Sun FJ, Jan YT, et al. Skeletal muscle loss is an imaging biomarker of outcome after definitive chemoradiotherapy for locally advanced cervical cancer. Clinical Cancer Research 2018;24:5028–36. https://doi.org/10.1158/1078-0432.CCR-18-0788/87612/AM/SKELETAL-MUSCLE-LOSS-IS-AN-IMAGING-BIOMARKER-OF.

[34]    Han Q, Kim SI, Yoon SH, Kim TM, Kang HC, Kim HJ, et al. Impact of Computed Tomography-Based, Artificial Intelligence-Driven Volumetric Sarcopenia on Survival Outcomes in Early Cervical Cancer. Front Oncol 2021;11:741071. https://doi.org/10.3389/FONC.2021.741071/BIBTEX.

[35]    Lee WJ, Liu LK, Peng LN, Lin MH, Chen LK. Comparisons of sarcopenia defined by IWGS and EWGSOP criteria among older people: results from the I-Lan longitudinal aging study. J Am Med Dir Assoc 2013;14:528.e1-528.e7. https://doi.org/10.1016/J.JAMDA.2013.03.019.

[36]    Baracos V, Kazemi-Bajestani SMR. Clinical outcomes related to muscle mass in humans with cancer and catabolic illnesses. Int J Biochem Cell Biol 2013;45:2302–8. https://doi.org/10.1016/J.BIOCEL.2013.06.016.

[37]    Rinninella E, Cintoni M, Raoul P, Pozzo C, Strippoli A, Bria E, et al. Muscle mass, assessed at diagnosis by L3-CT scan as a prognostic marker of clinical outcomes in patients with gastric cancer: A systematic review and meta-analysis. Clin Nutr 2020;39:2045–54. https://doi.org/10.1016/J.CLNU.2019.10.021.

[38]    Shen W, Punyanitya M, Wang ZM, Gallagher D, St.-Onge MP, Albu J, et al. Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. J Appl Physiol (1985) 2004;97:2333–8. https://doi.org/10.1152/JAPPLPHYSIOL.00744.2004.
GALLERY